Market Place
Sourcing Support
Sanofi completes the acquisition of Dynavax
10 Feb 2026 //
PRESS RELEASE
Sanofi to acquire Dynavax, Pushes Ahead on Adult Vaccines
27 Dec 2025 //
PRESS RELEASE
Dynavax Enters License Agreement for Vaxart`s Oral COVID Vaccine
05 Nov 2025 //
PR NEWSWIRE
Dynavax Unveils Q3 2025 Financials, Launches $100M Share Buyback
05 Nov 2025 //
PR NEWSWIRE
Dynavax Reveals Phase 1/2 Shingles Vaccine Trial Results
22 Oct 2025 //
PR NEWSWIRE
Dynavax Reveals Promising Phase 1/2 Results for Shingles Vaccine
21 Aug 2025 //
PR NEWSWIRE
Dynavax Reports Second Quarter 2025 Financial Results
08 Aug 2025 //
PR NEWSWIRE
Dynavax Files Preliminary Proxy Statement
03 Apr 2025 //
PR NEWSWIRE
Dynavax Announces Debt Refinancing and Stock Repurchase
06 Mar 2025 //
PR NEWSWIRE
Dynavax drops Tdap vaccine after mulling ph. 1 data, competition
09 Nov 2024 //
FIERCE BIOTECH
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
27 Jun 2024 //
PR NEWSWIRE
Dynavax to Present at Upcoming Investor Conferences
28 May 2024 //
PR NEWSWIRE
Dynavax Provides US Regulatory Update On HEPLISAV-B 4-Dose Hemodialysis Regimen
14 May 2024 //
PR NEWSWIRE
Dynavax: Q1 2024 Financial Results, Business Updates
08 May 2024 //
PR NEWSWIRE
Dynavax Reports Q1 2024 Results on May 8
24 Apr 2024 //
PR NEWSWIRE
Dynavax to Present at TD Cowen`s 44th Annual Health Care Conference
27 Feb 2024 //
PR NEWSWIRE
Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results
08 Feb 2024 //
PR NEWSWIRE
Dynavax Announces Fourth Quarter and Full Year 2023 Financial Highlights
08 Jan 2024 //
PR NEWSWIRE
Dynavax Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
PR NEWSWIRE
Dynavax to Report Third Quarter 2023 Financial Results
26 Oct 2023 //
PR NEWSWIRE
Dynavax to Present at H.C. Wainwright 4th Annual Hepatitis B Virus Conference
19 Oct 2023 //
PR NEWSWIRE
Dynavax to Report Second Quarter 2023 Financial Results
20 Jul 2023 //
PR NEWSWIRE
Dynavax to Present at Upcoming Investor Conferences
30 May 2023 //
PR NEWSWIRE
Dynavax to Present at the JMP Securities Life Sciences Conference
08 May 2023 //
PR NEWSWIRE
Dynavax Reports First Quarter 2023 Financial Results
02 May 2023 //
PR NEWSWIRE
Dynavax to Present at the Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
PR NEWSWIRE
Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B
28 Feb 2023 //
PR NEWSWIRE
Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
PR NEWSWIRE
Dynavax Announces Uplisting to the Nasdaq Global Select Market
31 Jan 2023 //
PR NEWSWIRE
Dynavax Announces Preliminary Unaudited Fourth Quarter Financial Results
09 Jan 2023 //
PR NEWSWIRE
